SCHEMBL1574498

SCHEMBL1574498

O=C(Nc1ccccc1Cl)N1CC(N(CCO)CCO)C1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.53
TAS1R1 Q7RTX1 1/20 0.53
TAS1R2 Q8TE23 1/20 0.53
FAAH O00519 2/20 0.50
P2RX7 Q99572 1/20 0.49
GAA P10253 3/20 0.48
TSHR P16473 1/20 0.48
ALDH1A1 P00352 4/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 3/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575295 0.89 GAA (0.53) TAS1R3TAS1R1TAS1R2FAAHP2RX7
SCHEMBL1574839 0.86 GAA (0.55) TAS1R3TAS1R1TAS1R2FAAHP2RX7
SCHEMBL1575289 0.85 KDM4E (0.59) TAS1R3TAS1R1TAS1R2FAAHGAA
SCHEMBL1576522 0.84 TAAR1 (0.51) TAS1R3TAS1R1TSHRKDM4EKMT2A
SCHEMBL1575912 0.82 KDM4E (0.53) GAATSHRALDH1A1HPGDKDM4E
SCHEMBL1575120 0.82 TAS1R3 (0.51) TAS1R3TAS1R1TAS1R2FAAHP2RX7
SCHEMBL1575584 0.81 GRIN2B (0.51) FAAHALDH1A1HPGDKDM4EMAPT
SCHEMBL1574873 0.80 ALDH1A1 (0.53) GAAALDH1A1KMT2AMEN1MAPT
SCHEMBL1575390 0.79 NPSR1 (0.52) ALDH1A1KMT2AMEN1MAPTPOLB
SCHEMBL1574671 0.79 ALOX5 (0.54) TAS1R3TAS1R1TAS1R2FAAHGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB TAS1R3 4140/4885TAS1R1 4237/4885TAS1R2 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.